196 related articles for article (PubMed ID: 38477495)
1. Trilobatin contributes to the improvement of myopathy in a mouse model of Duchenne muscular dystrophy.
Hermes TA; Fratini P; Nascimento BG; Ferreira LL; Petri G; Fonseca FLA; Carvalho AAS; Feder D
Int J Exp Pathol; 2024 Apr; 105(2):75-85. PubMed ID: 38477495
[TBL] [Abstract][Full Text] [Related]
2. Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice.
Micheletto MLJ; Hermes TA; Bertassoli BM; Petri G; Perez MM; Fonseca FLA; Carvalho AAS; Feder D
Int J Exp Pathol; 2021 Feb; 102(1):11-21. PubMed ID: 33296126
[TBL] [Abstract][Full Text] [Related]
3. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine.
Moraes LH; de Burgos RR; Macedo AB; de Almeida Hermes T; de Faria FM; Minatel E
Biol Trace Elem Res; 2015 Sep; 167(1):115-20. PubMed ID: 25762099
[TBL] [Abstract][Full Text] [Related]
5. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
7. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
[TBL] [Abstract][Full Text] [Related]
8. Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology.
Reay DP; Yang M; Watchko JF; Daood M; O'Day TL; Rehman KK; Guttridge DC; Robbins PD; Clemens PR
Neurobiol Dis; 2011 Sep; 43(3):598-608. PubMed ID: 21624467
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy.
Dubuisson N; Davis-López de Carrizosa MA; Versele R; Selvais CM; Noel L; Van den Bergh PYD; Brichard SM; Abou-Samra M
Front Immunol; 2022; 13():1049076. PubMed ID: 36569900
[TBL] [Abstract][Full Text] [Related]
10. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
[TBL] [Abstract][Full Text] [Related]
11. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
[TBL] [Abstract][Full Text] [Related]
12. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle.
Eghtesad S; Jhunjhunwala S; Little SR; Clemens PR
Mol Med; 2011; 17(9-10):917-24. PubMed ID: 21607286
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
15. Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice.
Nakae Y; Stoward PJ; Kashiyama T; Shono M; Akagi A; Matsuzaki T; Nonaka I
J Mol Histol; 2004 Jun; 35(5):489-99. PubMed ID: 15571326
[TBL] [Abstract][Full Text] [Related]
16. Cathelicidin-related antimicrobial peptide mediates skeletal muscle degeneration caused by injury and Duchenne muscular dystrophy in mice.
Choi MC; Jo J; Lee M; Park J; Yao TP; Park Y
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3091-3105. PubMed ID: 36059045
[TBL] [Abstract][Full Text] [Related]
17. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice.
Messina S; Altavilla D; Aguennouz M; Seminara P; Minutoli L; Monici MC; Bitto A; Mazzeo A; Marini H; Squadrito F; Vita G
Am J Pathol; 2006 Mar; 168(3):918-26. PubMed ID: 16507907
[TBL] [Abstract][Full Text] [Related]
18. Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice.
Altamirano F; Valladares D; Henríquez-Olguín C; Casas M; López JR; Allen PD; Jaimovich E
PLoS One; 2013; 8(12):e81222. PubMed ID: 24349043
[TBL] [Abstract][Full Text] [Related]
19. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
[TBL] [Abstract][Full Text] [Related]
20. Vector-mediated expression of muscle specific kinase restores specific force to muscles in the mdx mouse model of Duchenne muscular dystrophy.
Ban J; Beqaj B; Phillips WD
Exp Physiol; 2021 Aug; 106(8):1794-1805. PubMed ID: 34114278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
